Enzalutamide (marketed as Xtandi and formerly known as MDV3100) is an androgen receptor antagonist drug developed by the pharmaceutical company Medivation for the treatment of metastatic castration-resistant prostate cancer.
Medivation has reported up to an 89% decrease in prostate specific antigen serum levels after a month of taking the medicine.
Early preclinical studies also suggest that enzalutamide inhibits breast cancer cell growth.
In August 2012, the U.S. Food and Drug (...)
humpath.com supports the 2014 edition of the European Symposium of Biopathology, June 19th and 20th 2014 in Paris, France.
Macroscopy, Microscopy, Videos, Digital slides, Virtual slides, Digital pathology, Biopathology, Molecular Pathology
Most recent articles
06/24/2014 : New trends in Pathology Informatics http://www.european-hospital.com/en/article/11952.html
Blinatumomab (MT103) is a anti-CD19 drug that has anti-cancer properties. It belongs to a new class of constructed monoclonal antibodies, bi-specific T-cell engagers (BiTEs), that exert action selectively and direct the human immune system to act against tumor cells.
Blinatumomab specifically targets the CD19 antigen present on B cells.
The drug was developed by a German-American company Micromet, Inc. in cooperation with (...)
Usually affects head of epididymis
May be due to ischemia with secondary granulomatous reaction and scarring
In a histologic review of adult epididymides obtained at autopsy (both epididymides of 408 men) or during surgery (261 men with testicular or epididymal nontumoral pathology), a peculiar granulomatous lesion was observed in two autopsy specimens (unilateral) and three surgical specimens. (#9255259#)
The lesion is located in the caput epididymidis and consists of a zone of (...)
The goal of the SKY/M-FISH and CGH database is to provide a public platform for investigators to share and compare their molecular cytogenetic data. The database is open to everyone and all users can view an individual investigator’s public data or compare public cases from different investigators.
Those wishing to contribute their own data must register and can choose to keep their data private for a period not to exceed two (...)
The Progenetix database provides an overview of copy number abnormalities in human cancer from currently 31915 array and chromosomal Comparative Genomic Hybridization (CGH) experiments.
Additionally, the website attempts to identify and present all publications (currently 2503 articles), referring to cancer genome profiling experiments.The database & software are developed by the group of Michael Baudis at the University of (...)
TICdb is a database of Translocation breakpoints In Cancer. This update contains 1,374 fusion sequences found in human tumors, involving 431 different genes.
For every fusion, TICdb will return the HGNC name of both partner genes and the original reference (either a GenBank or a Pubmed ID), as well as the fusion sequence.
TICdb team has also developed ONCOFUSE, a bayesian classifier that predicts the oncogenic potential of fusion genes found by (...)
Solid tumor entries in The Atlas of Genetics and Cytogenetics in Oncology and Haematology http://atlasgeneticsoncology.org/
0 Adrenal cortical carcinoma Angiomatoid Fibrous Histiocytoma Bladder: Squamous cell carcinoma Bladder: Urothelial carcinomas Bone: Adamantinoma 5 Bone: Aneurysmal bone cysts Bone: Angiosarcoma Bone: Chondroblastoma Bone: Chondroma Bone: Chondromyxoid fibroma 10 Bone: Chondrosarcoma Bone: Conventional Osteosarcoma Bone: Dedifferentiated chondrosarcoma Bone: (...)
Dabrafenib (trade name Tafinlar) is a drug for the treatment of cancers associated with a mutated version of the gene BRAF.
Dabrafenib acts as an inhibitor of the associated enzyme B-Raf, which plays a role in the regulation of cell growth.
Dabrafenib has clinical activity with a manageable safety profile in clinical trials of phase 1 and 2 in patients with BRAF(V600)-mutated metastatic (...)